In his new role, Mr Garbarini is responsible for Ferring’s two marketed products in these areas, euflexxa (1% sodium hyaluronate) for the pain caused by knee osteoarthritis, and Prosed DS for the relief of discomfort of the lower urinary tract. He will also oversee the US sales and marketing of Ferring’s pipeline of urology products, including a GnRH antagonist for prostate cancer.
Prior to joining Ferring, Garbarini was director, client services for Caresoft. Previously, he served in various positions at Schering-Plough/Key Pharmaceuticals, Lowe McAdams Healthcare advertising agency, and Glaxo Wellcome, where he was honored as a top sales representative.
Wayne Anderson, president of Ferring, said: “Bill’s talent, leadership and wealth of experience in pharmaceutical marketing have driven his rapid rise and recognition in the healthcare industry. After spearheading the growth of our infertility and orthopaedics businesses, he is extremely qualified to lead our new orthopaedics and urology unit.”